Difference between revisions of "Acinic cell carcinoma"

From Libre Pathology
Jump to navigation Jump to search
 
(6 intermediate revisions by the same user not shown)
Line 98: Line 98:
*Nuclear atypia.
*Nuclear atypia.
*[[Perineural invasion]].
*[[Perineural invasion]].
*[[Mitoses]].
*Mitoses.
*Infiltrative margin.
*Infiltrative margin.
*Tumour sclerosis.
*Tumour sclerosis.
Line 112: Line 112:


==IHC==
==IHC==
*CK7 +ve.<ref name=pmid26166029>{{cite journal |vauthors=Li X, Shi Z, Wang Y, Liu Y, Liu T |title=Immunohistochemical expression of cytokeratins in human salivary gland acinic cell carcinomas |journal=Oral Surg Oral Med Oral Pathol Oral Radiol |volume=120 |issue=2 |pages=248–57 |date=August 2015 |pmid=26166029 |doi=10.1016/j.oooo.2015.04.014 |url=}}</ref>
*CK7 +ve.<ref name=pmid26166029>{{cite journal |authors=Li X, Shi Z, Wang Y, Liu Y, Liu T |title=Immunohistochemical expression of cytokeratins in human salivary gland acinic cell carcinomas |journal=Oral Surg Oral Med Oral Pathol Oral Radiol |volume=120 |issue=2 |pages=248–57 |date=August 2015 |pmid=26166029 |doi=10.1016/j.oooo.2015.04.014 |url=}}</ref>
*CK19 +ve.<ref name=pmid26166029/>
*CK19 +ve.<ref name=pmid26166029/>
*NR4A3 +ve (nuclear) (5 of 6 cases<ref name=pmid33959239>{{cite journal |authors=Owosho A, Tyler D, Adesina O, Odujoko O, Summersgill K |title=NR4A3 (NOR-1) Immunostaining Shows Better Performance than DOG1 Immunostaining in Acinic Cell Carcinoma of Salivary Gland: a Preliminary Study |journal=J Oral Maxillofac Res |volume=12 |issue=1 |pages=e4 |date=2021 |pmid=33959239 |pmc=8085676 |doi=10.5037/jomr.2021.12104 |url=}}</ref>; 18 of 20 cell blocks<ref name=pmid26166029>{{cite journal |authors=Li X, Shi Z, Wang Y, Liu Y, Liu T |title=Immunohistochemical expression of cytokeratins in human salivary gland acinic cell carcinomas |journal=Oral Surg Oral Med Oral Pathol Oral Radiol |volume=120 |issue=2 |pages=248–57 |date=August 2015 |pmid=26166029 |doi=10.1016/j.oooo.2015.04.014 |url=}}</ref>; 9 of 9 surgicals<ref name=pmid26166029/>).
*Alpha1-ACT (also ''AACT'') +ve.
Negative:
*S-100 -ve.
*S-100 -ve.
*p63 -ve (30 -ve of 30 cases<ref name=pmid23054955/>).
*p63 -ve (30 -ve of 30 cases<ref name=pmid23054955/>).
**p63 +ve in [[mucoepidermoid carcinoma]] (24 +ve of 24 cases<ref name=pmid23054955>{{Cite journal  | last1 = Sams | first1 = RN. | last2 = Gnepp | first2 = DR. | title = P63 expression can be used in differential diagnosis of salivary gland acinic cell and mucoepidermoid carcinomas. | journal = Head Neck Pathol | volume = 7 | issue = 1 | pages = 64-8 | month = Mar | year = 2013 | doi = 10.1007/s12105-012-0403-2 | PMID = 23054955 }}</ref>18 of 20 cell blocks;<ref name=pmid26166029>{{cite journal |vauthors=Li X, Shi Z, Wang Y, Liu Y, Liu T |title=Immunohistochemical expression of cytokeratins in human salivary gland acinic cell carcinomas |journal=Oral Surg Oral Med Oral Pathol Oral Radiol |volume=120 |issue=2 |pages=248–57 |date=August 2015 |pmid=26166029 |doi=10.1016/j.oooo.2015.04.014 |url=}}</ref>; 9 of 9 surgicals<ref name=pmid26166029/>
**p63 +ve in [[mucoepidermoid carcinoma]] (24 +ve of 24 cases<ref name=pmid23054955>{{Cite journal  | last1 = Sams | first1 = RN. | last2 = Gnepp | first2 = DR. | title = P63 expression can be used in differential diagnosis of salivary gland acinic cell and mucoepidermoid carcinomas. | journal = Head Neck Pathol | volume = 7 | issue = 1 | pages = 64-8 | month = Mar | year = 2013 | doi = 10.1007/s12105-012-0403-2 | PMID = 23054955 }}</ref>).


*NR4A3 +ve (nuclear) (5 of 6 cases<ref name=pmid33959239>{{cite journal |vauthors=Owosho A, Tyler D, Adesina O, Odujoko O, Summersgill K |title=NR4A3 (NOR-1) Immunostaining Shows Better Performance than DOG1 Immunostaining in Acinic Cell Carcinoma of Salivary Gland: a Preliminary Study |journal=J Oral Maxillofac Res |volume=12 |issue=1 |pages=e4 |date=2021 |pmid=33959239 |pmc=8085676 |doi=10.5037/jomr.2021.12104 |url=}}</ref>; 18 of 20 cell blocks<ref name=pmid26166029>{{cite journal |vauthors=Li X, Shi Z, Wang Y, Liu Y, Liu T |title=Immunohistochemical expression of cytokeratins in human salivary gland acinic cell carcinomas |journal=Oral Surg Oral Med Oral Pathol Oral Radiol |volume=120 |issue=2 |pages=248–57 |date=August 2015 |pmid=26166029 |doi=10.1016/j.oooo.2015.04.014 |url=}}</ref>; 9 of 9 surgicals<ref name=pmid26166029/>).
A panel: CK7, CK19, AACT, mammaglobin, S-100, GATA3.
*Alpha1-ACT (also AACT) +Ve.
 
There are a bunch of other [[stains]] that are touted to be useful (amylase, anti-chymotrypsin, lactoferrin). Weinreb thinks these are '''not''' helpful.<ref name=IW_10jan2011>IW. 11 January 2011.</ref>


==Molecular==
==Molecular==
*t(4;9)(q13;q31).<ref name=pmid33959239>{{cite journal |vauthors=Owosho A, Tyler D, Adesina O, Odujoko O, Summersgill K |title=NR4A3 (NOR-1) Immunostaining Shows Better Performance than DOG1 Immunostaining in Acinic Cell Carcinoma of Salivary Gland: a Preliminary Study |journal=J Oral Maxillofac Res |volume=12 |issue=1 |pages=e4 |date=2021 |pmid=33959239 |pmc=8085676 |doi=10.5037/jomr.2021.12104 |url=}}</ref>  
*t(4;9)(q13;q31).<ref name=pmid33959239>{{cite journal |authors=Owosho A, Tyler D, Adesina O, Odujoko O, Summersgill K |title=NR4A3 (NOR-1) Immunostaining Shows Better Performance than DOG1 Immunostaining in Acinic Cell Carcinoma of Salivary Gland: a Preliminary Study |journal=J Oral Maxillofac Res |volume=12 |issue=1 |pages=e4 |date=2021 |pmid=33959239 |pmc=8085676 |doi=10.5037/jomr.2021.12104 |url=}}</ref>  
**''Secretory Ca-binding phosphoprotein'' (SCPP) at 4q13.<ref name=pmid30664630>{{cite journal |vauthors=Haller F, Bieg M, Will R, Körner C, Weichenhan D, Bott A, Ishaque N, Lutsik P, Moskalev EA, Mueller SK, Bähr M, Woerner A, Kaiser B, Scherl C, Haderlein M, Kleinheinz K, Fietkau R, Iro H, Eils R, Hartmann A, Plass C, Wiemann S, Agaimy A |title=Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands |journal=Nat Commun |volume=10 |issue=1 |pages=368 |date=January 2019 |pmid=30664630 |pmc=6341107 |doi=10.1038/s41467-018-08069-x |url=}}</ref>
**''Secretory Ca-binding phosphoprotein'' (SCPP) at 4q13.<ref name=pmid30664630>{{cite journal |authors=Haller F, Bieg M, Will R, Körner C, Weichenhan D, Bott A, Ishaque N, Lutsik P, Moskalev EA, Mueller SK, Bähr M, Woerner A, Kaiser B, Scherl C, Haderlein M, Kleinheinz K, Fietkau R, Iro H, Eils R, Hartmann A, Plass C, Wiemann S, Agaimy A |title=Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands |journal=Nat Commun |volume=10 |issue=1 |pages=368 |date=January 2019 |pmid=30664630 |pmc=6341107 |doi=10.1038/s41467-018-08069-x |url=}}</ref>
**''Nuclear Receptor Subfamily 4 Group A Member 3'' (NR4A3) at 9q31.<ref name=pmid30664630/>
**''Nuclear Receptor Subfamily 4 Group A Member 3'' (NR4A3) at 9q31.<ref name=pmid30664630/>


Line 142: Line 143:


Comment:
Comment:
Immunostains are in keeping with acinic cell carcinoma (mammaglobin, S-100 and p63 are all NEGATIVE). A PAS stain is positive in the tumour.
The tumour stains as follows:
POSITIVE: CK7, CK19, AACT, PAS.
NEGATIVE: mammaglobin, S-100, p63.
 
The staining is in keeping with acinic cell carcinoma.
</pre>
</pre>


Latest revision as of 16:54, 27 October 2021

Acinic cell carcinoma
Diagnosis in short

Acinic cell carcinoma. H&E stain.
LM "acinic cells" (abundant finely vacuolated cytoplasm with basophilic granules, small nuclei with stippled chromatin), scattered "intercalcated duct type cells" (eosinophilic cytoplasm with moderate amount of cytoplasm and bland nuclei), +/-peri-tumoural lymphocytes, +/-glassy extracellular bluish/purple blobs
Subtypes oncocytic variant, clear cell variant, papillary cystic variant
LM DDx oncocytoma of the salivary gland, mucoepidermoid carcinoma, adenocarcinoma NOS, secretory carcinoma of the salivary gland
Stains PAS +ve, PASD +ve
IHC p63 -ve, S-100 -ve, CK7 +ve, CK19 +ve, NR4A3 +ve, alpha1-ACT +ve
EM zymogen granules
Molecular t(4;9)(q13;q31)
Gross tan or reddish
Site salivary gland - usu. parotid gland
Signs salivary gland mass
Prevalence uncommon
Prognosis good

Acinic cell carcinoma, abbreviated AcCC, is a rare type of salivary gland cancer. It is also known as acinic cell adenocarcinoma.

It should not to be confused with pancreatic acinar cell carcinoma.

General

  • Malignant neoplasm of salivary gland arising from acinic cells.
  • The relative prevalence of the neoplasm in the various salivary gland reflects the abundance of acinic cells: parotid gland (~80%) > minor salivary glands (~17%) > submandibular glands (~3%).
  • Affects wide age range -- including children.
  • Site affect prognosis (most aggressive to least aggressive): submandibular > parotid > minor salivary.
  • Good prognosis - in one large cohort:[1]
    • ~97% five year survival.
    • ~93% 10 year survival.

Gross

  • Tan or reddish.

Microscopic

Features:

  • Sheets of acinic cells with:
    • Abundant finely vacuolated cytoplasm with basophilic granules - key feature.
      • Granules may be focal.
    • Small nuclei stippled chromatin.
  • Scattered intercalcated duct type cells with:
    • Eosinophilic cytoplasm with moderate amount of cytoplasm.
    • Bland nuclei with slightly larger than seen in acinic cells.
  • +/-Peri-tumoural lymphocytes.
  • +/-Glassy extracellular bluish/purple blobs.

Notes:

  • Adipose tissue -- present in the salivary glands -- is absent in AcCC.
  • May focally resemble thyroid tissue.
  • Smaller (characteristic) microvacuoles (unreported in the literature) may be present that have a bubbly appearance and glassy basophilic inclusions.[2]

Memory device:

  • AcCC - lots of "C"s - chromatin stipled, cytoplasm generous.

DDx:

Images

Case

  • AcCC - intermed. mag. (WC/Nephron)

  • AcCC - high mag. (WC/Nephron)

  • AcCC - very high mag. (WC/Nephron)

Case

  • AcCC - low mag. (WC/Nephron)

  • AcCC - intermed. mag. (WC/Nephron)

  • AcCC - high mag. (WC/Nephron)

  • AcCC - very high mag. (WC/Nephron)

  • AcCC - very high mag. (WC/Nephron)

www

Grading

General:

  • Not prognostic.
  • Done to avoid phone calls from clinician.

Factors Weinreb uses:[2]

Subtypes

  • Oncocytic variant - rare.
  • Clear cell variant - rare.
  • Papillary cystic variant.

Stains

  • PAS +ve.
  • PAS-D +ve.

IHC

  • CK7 +ve.[5]
  • CK19 +ve.[5]
  • NR4A3 +ve (nuclear) (5 of 6 cases[6]; 18 of 20 cell blocks[5]; 9 of 9 surgicals[5]).
  • Alpha1-ACT (also AACT) +ve.

Negative:

A panel: CK7, CK19, AACT, mammaglobin, S-100, GATA3.

Molecular

  • t(4;9)(q13;q31).[6]
    • Secretory Ca-binding phosphoprotein (SCPP) at 4q13.[8]
    • Nuclear Receptor Subfamily 4 Group A Member 3 (NR4A3) at 9q31.[8]

EM

Sign out

A. Tumour, Left Parotid Gland, Excision:
- ACINIC CELL CARCINOMA, see comment.
-- Margins clear.
-- Please see synoptic report.

B. Lymph Nodes, Left - Level 2 & 3, Lymphadenectomy:
- Five lymph nodes NEGATIVE for malignancy (0/5).

Comment:
The tumour stains as follows:
POSITIVE: CK7, CK19, AACT, PAS.
NEGATIVE: mammaglobin, S-100, p63.

The staining is in keeping with acinic cell carcinoma.

See also

References

  1. ↑ Patel, NR.; Sanghvi, S.; Khan, MN.; Husain, Q.; Baredes, S.; Eloy, JA. (Jan 2014). "Demographic trends and disease-specific survival in salivary acinic cell carcinoma: an analysis of 1129 cases.". Laryngoscope 124 (1): 172-8. doi:10.1002/lary.24231. PMID 23754708.
  2. ↑ 2.0 2.1 IW. 11 January 2011.
  3. ↑ Ihrler, S.; Blasenbreu-Vogt, S.; Sendelhofert, A.; Lang, S.; Zietz, C.; Löhrs, U. (2002). "Differential diagnosis of salivary acinic cell carcinoma and adenocarcinoma (NOS). A comparison of (immuno-)histochemical markers.". Pathol Res Pract 198 (12): 777-83. PMID 12608654.
  4. ↑ Lei, Y.; Chiosea, SI. (Jun 2012). "Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools.". Head Neck Pathol 6 (2): 166-70. doi:10.1007/s12105-011-0312-9. PMID 22127547.
  5. ↑ 5.0 5.1 5.2 5.3 Li X, Shi Z, Wang Y, Liu Y, Liu T (August 2015). "Immunohistochemical expression of cytokeratins in human salivary gland acinic cell carcinomas". Oral Surg Oral Med Oral Pathol Oral Radiol 120 (2): 248–57. doi:10.1016/j.oooo.2015.04.014. PMID 26166029.
  6. ↑ 6.0 6.1 Owosho A, Tyler D, Adesina O, Odujoko O, Summersgill K (2021). "NR4A3 (NOR-1) Immunostaining Shows Better Performance than DOG1 Immunostaining in Acinic Cell Carcinoma of Salivary Gland: a Preliminary Study". J Oral Maxillofac Res 12 (1): e4. doi:10.5037/jomr.2021.12104. PMC 8085676. PMID 33959239. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085676/.
  7. ↑ 7.0 7.1 Sams, RN.; Gnepp, DR. (Mar 2013). "P63 expression can be used in differential diagnosis of salivary gland acinic cell and mucoepidermoid carcinomas.". Head Neck Pathol 7 (1): 64-8. doi:10.1007/s12105-012-0403-2. PMID 23054955.
  8. ↑ 8.0 8.1 Haller F, Bieg M, Will R, Körner C, Weichenhan D, Bott A, Ishaque N, Lutsik P, Moskalev EA, Mueller SK, Bähr M, Woerner A, Kaiser B, Scherl C, Haderlein M, Kleinheinz K, Fietkau R, Iro H, Eils R, Hartmann A, Plass C, Wiemann S, Agaimy A (January 2019). "Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands". Nat Commun 10 (1): 368. doi:10.1038/s41467-018-08069-x. PMC 6341107. PMID 30664630. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341107/.
  9. ↑ Sun, Y.; Wasserman, PG. (Feb 2004). "Acinar cell carcinoma arising in the stomach: a case report with literature review.". Hum Pathol 35 (2): 263-5. PMID 14991547.
Retrieved from "https://librepathology.org/w/index.php?title=Acinic_cell_carcinoma&oldid=51581"